Calder Vale Peptides of Skipton closes after 4 years
A proper account of an operation that existed, and of what closing it cost.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 7 of 33 of this archive, newest first.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
Efficacy was never the question in this appraisal. Duration of treatment was.
Efficacy was never the question in this appraisal. Duration of treatment was.
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
Reported from the analysis, not from a warning notice.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.